Frédérique Penault–Llorca

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

Wendy De Roock, Bart Claes, David Bernasconi et al. · The Lancet Oncology · 2010 · 2.1K citations

Medicine, Oncology, Pharmacology +13

Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group

M. Dowsett, Torsten O. Nielsen, Roger A’Hern et al. · JNCI Journal of the National Cancer Institute · 2011 · 2K citations · Full text

Medicine, Cancer Biology, Oncology +8

<i>KRAS</i> Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab

Astrid Lièvre, Jean‐Baptiste Bachet, Valérie Boige et al. · Journal of Clinical Oncology · 2008 · 1.5K citations · Full text

Medicine, Oncology, Pharmacology +17

Trastuzumab for Patients With Axillary-Node–Positive Breast Cancer: Results of the FNCLCC-PACS 04 Trial

M. Spielmann, Henri Roché, T. Delozier et al. · Journal of Clinical Oncology · 2009 · 299 citations

Medicine, Oncology, Pharmacotherapy +17

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

Zuzana Kos, Elvire Roblin, Rim S. Kim et al. · npj Breast Cancer · 2020 · 206 citations · Full text

Medicine, Oncology, Pathology +16